This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zahn, E. M. Articles by Latson, L. A. Search for Related Content PubMed PubMed Citation Articles by Zahn, E. M. Articles by Latson, L. A. Related Collections Animal models of human disease Pediatric and congenital heart disease, including cardiovascular surgery

(Circulation. 2001;104:711.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Development and Testing of the Helex Septal Occluder, a New Expanded Polytetrafluoroethylene Atrial Septal Defect Occlusion System

Evan M. Zahn, MD; Neil Wilson, MD; Warren Cutright, DVM; Larry A. Latson, MD

From the Department of Cardiology, Miami Children’s Hospital, Miami, Fla (E.M.Z.); the Department of Cardiology, Royal Hospital for Sick Children, Glasgow, Scotland (N.W.); W.L. Gore and Associates, Flagstaff, Ariz (W.C.); and the Department of Pediatric Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio (L.A.L.).

Correspondence to Evan M. Zahn, MD, Miami Children’s Hospital, Suite 104, 3200 SW 60th Court, Miami, FL 33155. E-mail emzmch{at}aol.com

Background—— A variety of transcatheter atrial septal defect (ASD) occluders are currently in use around the world. Although for the most part effective, all of these devices lack features that would be desirable in a "perfect" device. The Helex septal occluder is a new type of device designed to improve the results of transcatheter ASD closure. This study was designed to examine the effectiveness and safety of this occluder in an animal model.

Methods and Results—— The Helex was implanted into 24 dogs with surgically created ASDs. Procedural details focusing on deployment, removal, and early closure rates were examined. Follow-up consisted of sequential transesophageal echocardiography and fluoroscopy as well as epicardial contrast echocardiography and angiography at the time of death. Specimens were examined grossly and histologically, and devices were tested for metal fatigue. All animals had successful ASD closure. Implantation was uncomplicated (mean fluoroscopy time 11.7 minutes), and removal or repositioning was always possible. Closure rate as judged by transesophageal echocardiography was 88% initially and 100% at 2-week follow-up. Devices rapidly became infiltrated with connective tissue without inflammation and were endothelialized over time. There were no instances of thromboembolism. A single wire-frame fracture occurred secondary to a prototype delivery system malfunction.

Conclusions—— The Helex septal occluder proved safe and effective for ASD closure. Several advantages over currently available devices were evident in this model. Controlled prospective clinical trials are needed.

Key Words: heart septal defects • catheterization • pediatrics • shunts

This article has been cited by other articles:

				T. K. Jones, L. A. Latson, E. Zahn, C. E. Fleishman, J. Jacobson, R. Vincent, K. Kanter, and Multicenter Pivotal Study of the HELEX Septal Occl Results of the U.S. Multicenter Pivotal Study of the HELEX Septal Occluder for Percutaneous Closure of Secundum Atrial Septal Defects J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2215 - 2221. [Abstract] [Full Text] [PDF]

				M. Sigler and C. Jux Biocompatibility of septal defect closure devices Heart, April 1, 2007; 93(4): 444 - 449. [Abstract] [Full Text] [PDF]

				C. Jux, H. Bertram, P. Wohlsein, M. Bruegmann, and T. Paul Interventional Atrial Septal Defect Closure Using a Totally Bioresorbable Occluder Matrix: Development and Preclinical Evaluation of the BioSTAR Device J. Am. Coll. Cardiol., July 4, 2006; 48(1): 161 - 169. [Abstract] [Full Text] [PDF]

				M. Pawelec-Wojtalik, J. Nozynski, M. Wojtalik, M. Piaszczynski, R. Surmacz, D. Bukowska, and W. Mrowczynski Is device closure for direct access valved stent implantation safe? Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 4 - 9. [Abstract] [Full Text] [PDF]

				J.-F. Piechaud Closing down: transcatheter closure of intracardiac defects and vessel embolisations Heart, December 1, 2004; 90(12): 1505 - 1510. [Full Text] [PDF]

				U. Krumsdorf, S. Ostermayer, K. Billinger, T. Trepels, E. Zadan, K. Horvath, and H. Sievert Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients J. Am. Coll. Cardiol., January 21, 2004; 43(2): 302 - 309. [Abstract] [Full Text] [PDF]

				J. W. Moore and D. S. Levi Transcatheter closure of atrial shunts: Focus on a lingering issue J. Am. Coll. Cardiol., January 21, 2004; 43(2): 310 - 312. [Full Text] [PDF]